PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis

Company Overview - Cardiol Therapeutics Inc. is a clinical-stage life sciences company focused on anti-inflammatory and anti-fibrotic therapies for heart disease [3] - The company's lead drug candidate, CardiolRx™, is an oral solution containing cannabidiol, currently in clinical development for heart disease treatment [3] Clinical Development - CardiolRx™ is entering a late-stage Phase III clinical trial named MAVERIC, targeting patients with recurrent pericarditis who are at high risk for recurrence [2] - The MAVERIC Program includes the Phase II MAvERIC-Pilot study, the Phase II/III MAVERIC-2 trial, and the planned Phase III MAVERIC-3 trial [4] - The company has also received FDA authorization for clinical studies evaluating CardiolRx™ for recurrent pericarditis and acute myocarditis [4] Market Opportunity - The market for recurrent pericarditis is significant, with CardiolRx™ positioned to fill critical gaps in current treatment options [2] - CardiolRx™ is expected to be safer, more cost-effective, and disease-modifying, potentially improving the standard of care for patients with recurrent pericarditis [2] Financial Position and Milestones - The company is focused on key upcoming milestones related to the clinical trials and market entry of CardiolRx™ [2] - Cardiol Therapeutics is also developing CRD-38, a novel drug formulation for heart failure, which has substantial healthcare cost implications in the U.S. exceeding $30 billion annually [4]